HighGravityData
Companies / Medical devices & equipment / EW

Edwards Lifesciences

EW · Medical devices & equipment sector group
Guidance from Edwards Lifesciences’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
38 items
Releases tracked
8
Latest release
Jul 23, 2026
Data checked
Jul 23, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Jul 23, 2026 release

Each item compared with the same item in the previous release (Apr 23, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
NewTotal salesfor Q3 FY2026—“between $1.63 and $1.71 billion”Filing ↗
NewAdjusted EPSfor FY2026—“$2.95 to $3.05”Filing ↗
NewAdjusted EPSfor Q3 FY2026—“$0.71 to $0.77”Filing ↗
NewAdjusted EPS growth at midpointfor FY2026—“17% at midpoint”Filing ↗
NewGross profit marginfor FY2026—“at the lower end of its full-year 78% to 79%”Filing ↗
NewGross profit marginfor FY2026—“lower end of its full-year 78% to 79% gross margin guidance”Filing ↗
NewEffective tax rate, excluding special itemsfor FY2026—“at the high end of its previous range of 16% to 19%”Filing ↗
NarrowedTAVR salesfor FY2026“$4.7 to $5.0 billion”“$4.75 billion to $5.0 billion”Filing ↗
NewTAVR sales growth (constant currency)for FY2026—“8% to 9%”Filing ↗
NewTMTT product group salesfor FY2026—“$760 to $780 million”Filing ↗
NewTotal company salesfor FY2026—“$6.6 billion to $6.9 billion”Filing ↗
NewTotal company sales growth (constant currency)for FY2026—“10% to 11%”Filing ↗
NewTotal company sales growth target, longer termfor the long term—“approximately 10% total company sales growth, on average”Filing ↗
ReiteratedConstant currency operating margin expansionfor FY2026“approximately 150 basis points”“approximately 150 basis points”Filing ↗
ReiteratedOperating profit marginfor FY2026“high end of the company’s original 28% to 3 29% guidance range”“high end of the company’s original 28% to 29% guidance range”Filing ↗
ReiteratedR&D expense as a percentage of salesfor FY2026“approximately 17%”“approximately 17%”Filing ↗
Show 8 items not restated in this release
ChangeMetricPeriodPreviousNowSource
Not restatedStructural heart therapies contributionsfor FY2026“Increasing contributions from an expanding set of structural heart therapies”—Filing ↗
Not restatedSurgical sales growthfor FY2026“mid-single-digit”—Filing ↗
Not restatedTAVR product group sales growth ratefor FY2026“7% to 9%”—Filing ↗
Not restatedTMTT growingfor FY2026“35 – 45%”—Filing ↗
Not restatedTMTT growthfor FY2026“35 – 45%”—Filing ↗
Not restatedOperating profit marginfor the long term“annual operating profit margin expansion thereafter”—Filing ↗
Not restatedR&D as a percentage of salesfor the long term“moderate R&D as a percentage of sales over time”—Filing ↗
Not restatedSG&A ratiofor the long term“lower SG&A ratio over time”—Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
TMTT revenue“$740 – $780 million”for FY2026GAAP-tiedFeb 10, 20261Filing ↗
TMTT revenue growth“35 – 45% to $740 – $780 million”for FY2026GAAP-tiedFeb 10, 20261Filing ↗
Total sales“between $1.63 and $1.71 billion”for Q3 FY2026GAAP-tiedJul 23, 20261Filing ↗
Adjusted EPS“$2.95 to $3.05”for FY2026Company-definedJul 23, 20261Filing ↗
Adjusted EPS“$0.71 to $0.77”for Q3 FY2026Company-definedJul 23, 20261Filing ↗
Adjusted EPS“$2.95 to $3.05”for FY2026Company-definedFeb 10, 20262Filing ↗
Adjusted EPS growth at midpoint“17% at midpoint”for FY2026Company-definedJul 23, 20261Filing ↗
Adjusted gross profit margin“between 78% and 79%”for FY2026Company-definedFeb 10, 20261Filing ↗
Constant currency operating margin expansion“approximately 150 basis points”for FY2026Company-definedApr 23, 20262Filing ↗
EPS“$2.90 to $3.05”for FY2026GAAP-tiedFeb 10, 20261Filing ↗
Gross margin“78% to 79%”for FY2026GAAP-tiedApr 23, 20261Filing ↗
Gross profit margin“at the lower end of its full-year 78% to 79%”for FY2026GAAP-tiedJul 23, 20261Filing ↗
Gross profit margin“lower end of its full-year 78% to 79% gross margin guidance”for FY2026GAAP-tiedJul 23, 20261Filing ↗
Operating profit margin“high end of the company’s original 28% to 29% guidance range”for FY2026GAAP-tiedApr 23, 20262Filing ↗
Operating profit margin“at the high end of the original 28% to 29% guidance range”for FY2026GAAP-tiedFeb 10, 20261Filing ↗
Constant currency sales growth“9% to 11%”for FY2026Company-definedApr 23, 20261Filing ↗
Constant currency sales growth“8 – 10%”for FY2026Company-definedFeb 10, 20261Filing ↗
Effective tax rate, excluding special items“at the high end of its previous range of 16% to 19%”for FY2026GAAP-tiedJul 23, 20261Filing ↗
R&D as a percentage of sales“approximately 17%”for FY2026Company-definedFeb 10, 20261Filing ↗
R&D expense as a percentage of sales“approximately 17%”for FY2026Company-definedApr 23, 20262Filing ↗
Sales growth rate“9% to 11%”for FY2026Company-definedApr 23, 20261Filing ↗
Sales growth rate“8 to 10%”for FY2026Company-definedFeb 10, 20261Filing ↗
Structural heart therapies contributions“Increasing contributions from an expanding set of structural heart therapies”for FY2026Company-definedFeb 11, 20251Filing ↗
Surgical sales growth“mid-single-digit”for FY2026Company-definedApr 23, 20261Filing ↗
TAVR product group sales growth rate“7% to 9%”for FY2026Company-definedApr 23, 20261Filing ↗
TAVR sales“$4.75 billion to $5.0 billion”for FY2026Company-definedApr 23, 20262Filing ↗
TAVR sales growth (constant currency)“8% to 9%”for FY2026Company-definedJul 23, 20261Filing ↗
TMTT growing“35 – 45%”for FY2026Company-definedFeb 10, 20261Filing ↗
TMTT growth“35 – 45%”for FY2026Company-definedFeb 10, 20261Filing ↗
TMTT product group sales“$760 to $780 million”for FY2026Company-definedJul 23, 20261Filing ↗
TMTT sales“$740 to $780 million”for FY2026Company-definedFeb 10, 20262Filing ↗
Total company sales“$6.6 billion to $6.9 billion”for FY2026Company-definedJul 23, 20261Filing ↗
Total company sales“$6.5 to $6.9 billion”for FY2026Company-definedApr 23, 20261Filing ↗
Total company sales growth (constant currency)“10% to 11%”for FY2026Company-definedJul 23, 20261Filing ↗
Long term
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Operating profit margin“annual operating profit margin expansion thereafter”for the long termGAAP-tiedFeb 11, 20251Filing ↗
R&D as a percentage of sales“moderate R&D as a percentage of sales over time”for the long termCompany-definedFeb 11, 20251Filing ↗
SG&A ratio“lower SG&A ratio over time”for the long termCompany-definedFeb 11, 20251Filing ↗
Total company sales growth target, longer term“approximately 10% total company sales growth, on average”for the long termCompany-definedJul 23, 20261Filing ↗

How one item moved

Adjusted EPS, for FY2026 — every statement across the year, each linked to its filing.

Feb 10, 2026
New
“$2.90 – $3.05”
Filing ↗
Apr 23, 2026
Narrowed
“$2.95 to $3.05”
Filing ↗

How your Medical devices & equipment sector group guides

12 companies in Medical devices & equipment. What they guide on, and who reported this season.

Most-guided metric families
Revenue
9
Organic growth
8
Adjusted EPS
8
Buybacks
6
GAAP EPS
5
Operating margin
4
Dividends
3
Gross margin
2
This season’s releases
MedtronicSep 1, 20263 changes
Becton DickinsonAug 6, 20264 changes
ResMedAug 6, 20260 changes
InsuletAug 5, 202625 changes
Zimmer BiometAug 5, 20263 changes
DexComJul 30, 20263 changes
StrykerJul 30, 20262 changes
Boston ScientificJul 29, 20265 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025FY2024Long-term
TMTT revenue2 statements———
Total sales3 statements4 statements——
Adjusted EPS4 statements8 statements——
Adjusted EPS2 statements———
Adjusted EPS growth at midpoint1 statement———
The full record for Edwards Lifesciences and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Jul 23, 2026FY2026 Q20001099800-26-00003816Open filing ↗
Apr 23, 2026FY2026 Q10001099800-26-00002114Open filing ↗
Feb 10, 2026FY2025 Q40001099800-26-00000614Open filing ↗
Oct 30, 2025FY2025 Q30001099800-25-0000593Open filing ↗
Jul 24, 2025FY2025 Q20001099800-25-0000377Open filing ↗
Apr 23, 2025FY2025 Q10001099800-25-0000207Open filing ↗
Feb 11, 2025FY2024 Q40001099800-25-00000312Open filing ↗
Oct 24, 2024FY2024 Q30001099800-24-0000845Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error